VEGFA and congenital rubella syndrome: The results showed that in cohort A (fluoropyrimidine, oxaliplatin, and irinotecan in combination or not with anti-vascular endothelial growth factor/epidermal growth factor receptor monoclonal antibody), the ORR was 33%, including 2 CRS; In cohort B (≥ 1 previous treatment), the ORR was 33%, including 5 CRS.